Comparative Pharmacology
Head-to-head clinical analysis: LIPO GANTRISIN versus UROPLUS SS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIPO GANTRISIN versus UROPLUS SS.
LIPO GANTRISIN vs UROPLUS SS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lipo Gantrisin is a liposomal formulation of sulfisoxazole, a sulfonamide antibiotic. It inhibits bacterial dihydropteroate synthase, blocking folate synthesis and thereby bacterial DNA replication.
Uroplus SS contains sulfamethoxazole and trimethoprim. Sulfamethoxazole inhibits bacterial dihydrofolic acid synthesis by competing with para-aminobenzoic acid (PABA) for dihydropteroate synthase. Trimethoprim inhibits bacterial dihydrofolate reductase, blocking reduction of dihydrofolate to tetrahydrofolate. The sequential blockade of folic acid metabolism produces bactericidal activity.
2-4 mL (80-160 mg sulfisoxazole equivalent) intramuscularly every 12 hours for 5-7 days.
4 grams orally once daily as a single dose or in divided doses for 10 to 14 days for urinary tract infections.
None Documented
None Documented
The terminal elimination half-life is approximately 7-12 hours in adults with normal renal function; prolonged to 20-50 hours in renal impairment (CrCl <30 mL/min). This necessitates dose adjustment in renal disease.
Terminal elimination half-life is 18–24 hours, allowing once-daily dosing; steady-state achieved in 3–5 days.
Lipo Gantrisin is excreted primarily renally (70-80%) as unchanged drug and its acetylated metabolite. Biliary/fecal elimination accounts for 20-30%, with enterohepatic recirculation present.
Renal: 70–80% as unchanged drug; fecal: 10–20% via biliary elimination; minimal hepatic metabolism.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic